Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 1, Pages 541-551
Publisher
Proceedings of the National Academy of Sciences
Online
2019-12-31
DOI
10.1073/pnas.1902145116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models
- (2018) Heinz Läubli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers
- (2018) Roni Manyevitch et al. Current Alzheimer Research
- Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
- (2018) Curtis J. Perry et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
- (2018) Sabine Hoves et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
- (2017) Karla R. Wiehagen et al. Cancer Immunology Research
- Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
- (2016) Shin Foong Ngiow et al. CANCER RESEARCH
- Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
- (2016) Caroline Baer et al. NATURE CELL BIOLOGY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
- (2015) A. Scholz et al. EMBO Molecular Medicine
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- The transcriptional control of the perforin locus
- (2015) Matthew E. Pipkin et al. IMMUNOLOGICAL REVIEWS
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth
- (2014) Kshitij Srivastava et al. CANCER CELL
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials
- (2014) Sufia Butt Hassan et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Anti-VEGF antibody enhances the antitumor effect of CD40
- (2014) Sathishkumar Selvaraj et al. INTERNATIONAL JOURNAL OF CANCER
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Toll-Like Receptor Signaling Pathways
- (2014) Takumi Kawasaki et al. Frontiers in Immunology
- gCMAP: user-friendly connectivity mapping with R
- (2013) Thomas Sandmann et al. BIOINFORMATICS
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
- (2013) L. P. Richman et al. Cancer Immunology Research
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
- (2010) Young Jun Koh et al. CANCER CELL
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation